title: European regulatory framework on the use and development of pharmaceuticals and radiopharmaceuticals for pediatrics.
abstract: A survey in 2000 revealed that only about 30% of the prescriptions in the European pediatric population were on the basis of evidence-based medicine (EbM). Less for radiopharmaceuticals and principally for diagnostics, radiologists throughout Europe are referred to the pediatric guidelines of the European Association of Nuclear Medicine (EANM), as none of the frequently used tracers have been evaluated in clinical trials in the different pediatric subgroups. Following a resolution to address the lack of EbM in children, the European Commission published the Pediatric Regulation EC 1901/2006 and its amendment EC 1902/2006, effective from 2007. This regulation foresees the development of evidence-based medicine in the pediatric population. This is effected through a set of principles like the mandatory pediatric investigation plan (PIP) to be included with the market authorization application (MAA), and the pediatric use market authorization (PUMA) for off-patent pharmaceuticals, and to a very small part radiopharmaceuticals with funding possibilities for pediatric-specific research through the 7th Framework Programme (7FP) of the European Union.
authors.affiliation: Faculty of Electrical Engineering and Information Technology, University of Applied Sciences, Offenburg, Germany.
authors.forename: Marguérite
authors.initials: M
authors.lastname: Mensonides-Harsema
authors.forename: Andreas
authors.initials: A
authors.lastname: Otte
mesh_terms: D055808:Drug Discovery / Q000331:legislation & jurisprudence*; D005060:Europe; D019317:Evidence-Based Medicine / Q000331:legislation & jurisprudence; D006801:Humans; D010372:Pediatrics / Q000331:legislation & jurisprudence*; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D012926:Social Control, Formal
chemical_list: D019275:Radiopharmaceuticals